# ZyVersa Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ZyVersa Therapeutics, Inc.). ## Overview ZyVersa Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing therapies for inflammatory and renal diseases. Its business centers on drug candidates and related intellectual property rather than commercialized products, with operations organized around research, development, and clinical-stage advancement. ## Products & services • Clinical-stage drug development for inflammatory diseases • Renal disease therapeutics research and development • Proprietary drug candidates and related intellectual property • Preclinical and clinical program advancement - **Inflammatory disease therapeutics** (50%) — Drug candidates and development programs targeting inflammatory pathways and related disorders. - **Renal disease therapeutics** (30%) — Research and development programs focused on kidney and renal-related diseases. - **Intellectual property and pipeline assets** (20%) — Patents, formulations, and other proprietary assets supporting the development pipeline. - Clinical-stage drug development for inflammatory diseases - Renal disease therapeutics research and development - Proprietary drug candidates and related intellectual property - Preclinical and clinical program advancement ## Customers ZyVersa does not appear to sell commercial products to end customers in the traditional sense; its economic counterparties are primarily investors, research partners, and future healthcare market participants. In a development-stage model, the eventual buyers of approved therapies would be hospitals, physicians, specialty pharmacies, and payers, but current activity is centered on advancing candidates toward those markets. - **Capital providers** (primary) — Equity investors and financing counterparties that fund the company’s development programs and corporate operations. - **Research collaborators** (secondary) — Scientific and development partners that may support preclinical or clinical work on pipeline assets. - **Future healthcare customers** (emerging) — Hospitals, physicians, specialty pharmacies, and payers that would buy approved therapies if programs succeed. - Investors funding clinical development and pipeline advancement - Research and development collaborators supporting drug programs - Future prescribers and healthcare systems for approved therapies - Payers and pharmacy channels that would reimburse commercial drugs ## Geography ZyVersa is headquartered in the United States and its business is organized from a U.S. corporate base. As a development-stage pharmaceutical company, its operating footprint is primarily tied to U.S. capital markets, U.S.-based management, and any clinical or research activities conducted through external partners. - Headquartered in the United States - Primary exposure is to U.S. capital markets and regulation - Clinical and research work may rely on external partners - No country-level revenue disclosure was provided ## Strategy The company’s strategic focus is to advance its therapeutic pipeline through research, development, and clinical validation. For a small biopharmaceutical issuer, progress on scientific milestones, financing access, and regulatory execution are central to building value and preserving optionality for partnering or commercialization. - **Advance pipeline candidates** (short-term) — Clinical and regulatory progress is the main driver of value in a development-stage biotech model. - **Secure financing** (short-term) — Biopharmaceutical development requires ongoing capital before product revenue exists. - **Preserve intellectual property** (medium-term) — Patent and proprietary asset protection supports partnering leverage and future commercialization. - Advance inflammatory and renal disease programs through development stages - Protect and expand intellectual property around pipeline assets - Use external financing to support ongoing R&D and operations - Position programs for partnering, licensing, or future commercialization ## Risks ZyVersa faces the typical risks of a development-stage biotech company: clinical failure, regulatory delay, and dependence on external financing before any product revenue is established. The company also disclosed market-structure risks tied to Nasdaq delisting and OTCQB quotation, which can reduce liquidity, limit investor access, and increase share-price volatility. - **Clinical development failure** [critical] — Drug candidates may not meet endpoints or safety requirements, which can eliminate pipeline value. - **Financing and dilution risk** [high] — The company relies on external capital to fund R&D before commercial revenues exist. - **Nasdaq delisting and OTC trading risk** [high] — Reduced exchange access can lower liquidity, widen spreads, and impair investor demand. - **Penny stock classification** [medium] — Broker-dealer suitability and sales practice rules can restrict trading and marketability. - **Regulatory and tax changes** [low] — Changes in laws or operations can affect compliance burden and effective tax rate. - Clinical programs may fail to demonstrate safety or efficacy - Regulatory approvals can be delayed or denied - Dependence on external financing can dilute shareholders - OTCQB quotation may reduce liquidity and market access - Penny stock status can limit broker-dealer support ## Accounting As a development-stage biotech, the most important accounting judgments typically relate to equity financing, stock-based compensation, and the valuation of any warrants or other derivative instruments. Investors should also watch for going-concern-related disclosures, because the timing and terms of financing can materially affect reported results and balance-sheet presentation. - **Equity financing and warrant accounting** — Can create non-cash gains/losses and affect dilution - **Stock-based compensation** — Affects reported operating loss and share count - **Fair value measurements** — Can introduce earnings volatility - **Going concern assessment** — May influence disclosure and investor perception - Equity financings and warrant accounting can affect dilution and equity classification - Stock-based compensation can be a meaningful non-cash expense - Fair value estimates for warrants or preferred stock may drive volatility - Going-concern and liquidity disclosures can affect financial statement interpretation --- *Last updated: 2026-04-29T05:11:57.909580+00:00*